Pharmaceutical contract manufacturer, Tubilux, has selected TraceLink’s serialisation solutions to help its customers with EU falsified medicines directive (EU FMD) compliance.
Selection
Tubilux provides services to major and emerging pharmaceutical companies and specialises in ophthalmic products, including the manufacture of ointments, gels and eye drops for a wide range of eye disorders. It has selected the TraceLink Life Sciences Cloud to enable its customers to meet the EU FMD regulations.
“Our long-standing history in the international pharmaceutical and contract manufacturing industry has enabled Tubilux to become the benchmark in ophthalmology and preferred business partner for a number of Italian and international companies. In order to preserve our valued client relationships, we chose TraceLink for its market leadership and ability to help us seamlessly provide serialisation through a simple integration and wide breadth of interoperability with our partners,” said a Tubilux spokesperson. “With over 30 clients, we could not afford to lose time and resources by establishing individual point-to-point connections with each customer. TraceLink’s network approach instantly transformed our serialisation project into a much easier and more manageable process.”
“EU FMD compliance is becoming a stark reality for companies that need to have serialisation in place by the February 2019 deadline. The TraceLink Life Sciences Cloud platform provides companies with an easy and fast path directly into the EU Hub,” said Shabbir Dahod, president and CEO of TraceLink. “Tubilux values our deep expertise on EU compliance and chose TraceLink to simplify the serialisation process while reducing costs and minimising complexities with data exchange. We look forward to partnering with Tubilux to help ensure EU FMD compliance for its customers in Europe.”